1. Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, New South Wales 2007, Australia.
2. Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle, Newcastle, New South Wales 2308, Australia.
3. Graduate School of Health, Discipline of Pharmacy, University of Technology Sydney, Sydney, New South Wales 2007, Australia.
4. Intensive Care Unit, John Hunter Hospital, Newcastle, New South Wales 2308, Australia.
5. Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent 9000, Belgium.
6. Department of Biochemistry and Pharmacology, University of Melbourne, Victoria 3010, Australia.
7. Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, Section of Anatomic Pathology, University of Messina, Messina 98100, Italy.
8. Rare Lung Disease Unit, Department of Clinical and Biological Sciences, University of Torino, San Luigi Gonzaga University Hospital Orbassano, Torino 10043, Italy.
9. Istituti Clinici Scientifici Maugeri, IRCCS, SpA Società Benefit, Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell’Apparato Cardio Respiratorio, Veruno, Novara 28100, Italy.
10. Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia.
11. Centenary Institute and University of Technology Sydney, Sydney, New South Wales 2006, Australia.
12. Ablynx N.V., a Sanofi company, Ghent 9052, Belgium.
13. Center for Medical Genetics and Cancer Research Institute Ghent (CRIG), Ghent University, Ghent 9000, Belgium.
14. Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università di Messina, Messina 98100, Italy.